{"pmid":32499832,"pmcid":"PMC7241590","title":"Pharmacologicaltreatment of COVID-19: lights and shadows.","text":["Pharmacologicaltreatment of COVID-19: lights and shadows.","At the end of December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China and then the entire world, forcing the World Health Organization to make the assessment that the coronavirus disease (COVID-19) can be characterized as a pandemic, the first ever caused by a coronavirus. To date, clinical evidence and guidelines based on reliable data and randomized clinical trials for the treatment of COVID-19 are lacking. In the absence of definitive management protocols, many treatments for COVID-19 are currently being evaluated and tested worldwide. Some of these options were soon abandoned due to ineffectiveness, while others showed promising results. The basic treatments are mainly represented by antiviral drugs, even if the evidence is not satisfactory. Among the antivirals, the most promising appears to be remdesivir. Corticosteroids and tocilizumab seem to guarantee positive results in selected patients so far, although the timing of starting therapy and the most appropriate therapeutic schemes remain to be clarified. Efficacy of the other drugs is still uncertain, and they are currently used as a cocktail of treatments in the absence of definitive guidelines. What will represent the real solution to the enormous problem taking place worldwide is the identification of a safe and effective vaccine, for which enormous efforts and investments are underway.","Drugs Context","Menzella, Francesco","Biava, Mirella","Barbieri, Chiara","Livrieri, Francesco","Facciolongo, Nicola","32499832"],"abstract":["At the end of December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China and then the entire world, forcing the World Health Organization to make the assessment that the coronavirus disease (COVID-19) can be characterized as a pandemic, the first ever caused by a coronavirus. To date, clinical evidence and guidelines based on reliable data and randomized clinical trials for the treatment of COVID-19 are lacking. In the absence of definitive management protocols, many treatments for COVID-19 are currently being evaluated and tested worldwide. Some of these options were soon abandoned due to ineffectiveness, while others showed promising results. The basic treatments are mainly represented by antiviral drugs, even if the evidence is not satisfactory. Among the antivirals, the most promising appears to be remdesivir. Corticosteroids and tocilizumab seem to guarantee positive results in selected patients so far, although the timing of starting therapy and the most appropriate therapeutic schemes remain to be clarified. Efficacy of the other drugs is still uncertain, and they are currently used as a cocktail of treatments in the absence of definitive guidelines. What will represent the real solution to the enormous problem taking place worldwide is the identification of a safe and effective vaccine, for which enormous efforts and investments are underway."],"journal":"Drugs Context","authors":["Menzella, Francesco","Biava, Mirella","Barbieri, Chiara","Livrieri, Francesco","Facciolongo, Nicola"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32499832","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.7573/dic.2020-4-6","keywords":["antivirals","biologics","coronavirus","corticosteroids","pneumonia","severe acute respiratory syndrome"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab","remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1668890966356918272,"score":9.490897,"similar":[{"pmid":32329520,"title":"Current pharmacological treatments for COVID-19: what's next?","text":["Current pharmacological treatments for COVID-19: what's next?","Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications.","Br J Pharmacol","Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa","32329520"],"abstract":["Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications."],"journal":"Br J Pharmacol","authors":["Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329520","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bph.15072","keywords":["covid-19","anti-inflammatory agents","antivirals","clinical practice","clinical research","immuno-modulatory agents","literature review","pharmacological treatments"],"e_drugs":["remdesivir","tocilizumab","lopinavir-ritonavir drug combination","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138494591827971,"score":182.40074},{"pmid":32320825,"pmcid":"PMC7166307","title":"Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.","text":["Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.","Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year.","Infect Genet Evol","Abd El-Aziz, Tarek Mohamed","Stockand, James D","32320825"],"abstract":["Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). A novel coronavirus was identified in December 2019 in Wuhan city, Hubei province, China. This virus represents a new strain that has not been previously identified in humans. The virus is now known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease is called coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared the novel coronavirus outbreak a global pandemic in March 2020. Despite rigorous global containment and quarantine efforts, the incidence of COVID-19 continues to rise, with more than 1,948,617 laboratory-confirmed cases and over 121,846 deaths worldwide. Currently, no specific medication is recommended to treat COVID-19 patients. However, governments and pharmaceutical companies are struggling to quickly find an effective drug to defeat the coronavirus. In the current review, we summarize the existing state of knowledge about COVID-19, available medications, and treatment options. Favilavir is an antiviral drug that is approved in Japan for common influenza treatment and is now approved to treat symptoms of COVID-19 in China. Moreover, Chloroquine and hydroxychloroquine, drugs used to treat malaria and arthritis, respectively, were recommended by the National Health Commission of the People's Republic of China for treatment of COVID-19. Presently, chloroquine and hydroxychloroquine are under investigation by the US Food and Drug Administration (FDA) as a treatment for COVID-19. The first COVID-19 vaccine is not expected to be ready for clinical trials before the end of the year."],"journal":"Infect Genet Evol","authors":["Abd El-Aziz, Tarek Mohamed","Stockand, James D"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320825","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.meegid.2020.104327","keywords":["covid-19","coronavirus","pathogenesis","sars-cov-2","severe acute respiratory syndrome","therapy","vaccines"],"locations":["Wuhan","Hubei","China","Japan","China"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138493599875072,"score":160.5007},{"pmid":32282022,"title":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.","text":["Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.","Importance: The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. Observations: No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19. Conclusions and Relevance: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.","JAMA","Sanders, James M","Monogue, Marguerite L","Jodlowski, Tomasz Z","Cutrell, James B","32282022"],"abstract":["Importance: The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. Observations: No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19. Conclusions and Relevance: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date."],"journal":"JAMA","authors":["Sanders, James M","Monogue, Marguerite L","Jodlowski, Tomasz Z","Cutrell, James B"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282022","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1001/jama.2020.6019","e_drugs":["remdesivir","Oseltamivir"],"topics":["Treatment"],"weight":1,"_version_":1666138491414642689,"score":157.08295},{"pmid":32147628,"title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19).","text":["Discovering drugs to treat coronavirus disease 2019 (COVID-19).","The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2.","Drug Discov Ther","Dong, Liying","Hu, Shasha","Gao, Jianjun","32147628"],"abstract":["The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2."],"journal":"Drug Discov Ther","authors":["Dong, Liying","Hu, Shasha","Gao, Jianjun"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32147628","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.5582/ddt.2020.01012","keywords":["2019-ncov","covid-19","sars-cov-2","novel coronavirus","pneumonia"],"locations":["China","Japan","South Korea","China"],"countries":["Japan","China","Korea, Republic of"],"countries_codes":["JPN|Japan","CHN|China","KOR|Korea, Republic of"],"e_drugs":["remdesivir","Chloroquine","arbidol","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138492731654144,"score":154.86182},{"pmid":32503817,"title":"Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.","text":["Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.","Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), initially termed 2019-new CoV (2019-nCoV), is a novel coronavirus responsible for the severe respiratory illness currently ongoing worldwide from the beginning of December 2019. This beta gene virus, very close to bat coronaviruses (bat-CoV-RaTG13) and bat-SL-CoVZC45, causes a severe disease, similar to those caused by Middle East respiratory syndrome (MERS)-CoV and SARS-CoV viruses, featured by low to moderate mortality rate. Unfortunately, the antiviral drugs commonly used in clinical practice to treat viral infections, are not applicable to SARS-Cov-2 and no vaccine is available. Thus, it is extremely necessary to identify new drugs suitable for the treatment of the 2019-nCoV outbreak. Different preclinical studies conducted on other coronaviruses suggested that promising clinical outcomes for 2019-nCoV should be obtained by using alpha-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory drugs. Moreover, clinical trials with these suitable drugs should be performed on patients affected by SARS-Cov-2 to prove their efficacy and safety. Finally, a very promising therapeutic drug, tocilizumab, is discussed; it is currently used to treat patients presenting COVID-19 pneumonia. Herein, we recapitulate these experimental studies to highlight the use of antiviral drugs for the treatment of SARS-Cov-2 disease.","In Vivo","Bimonte, Sabrina","Crispo, Anna","Amore, Alfonso","Celentano, Egidio","Cuomo, Arturo","Cascella, Marco","32503817"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), initially termed 2019-new CoV (2019-nCoV), is a novel coronavirus responsible for the severe respiratory illness currently ongoing worldwide from the beginning of December 2019. This beta gene virus, very close to bat coronaviruses (bat-CoV-RaTG13) and bat-SL-CoVZC45, causes a severe disease, similar to those caused by Middle East respiratory syndrome (MERS)-CoV and SARS-CoV viruses, featured by low to moderate mortality rate. Unfortunately, the antiviral drugs commonly used in clinical practice to treat viral infections, are not applicable to SARS-Cov-2 and no vaccine is available. Thus, it is extremely necessary to identify new drugs suitable for the treatment of the 2019-nCoV outbreak. Different preclinical studies conducted on other coronaviruses suggested that promising clinical outcomes for 2019-nCoV should be obtained by using alpha-interferon, chloroquine phosphate, arabinol, remdesivir, lopinavir/ritonavir, and anti-inflammatory drugs. Moreover, clinical trials with these suitable drugs should be performed on patients affected by SARS-Cov-2 to prove their efficacy and safety. Finally, a very promising therapeutic drug, tocilizumab, is discussed; it is currently used to treat patients presenting COVID-19 pneumonia. Herein, we recapitulate these experimental studies to highlight the use of antiviral drugs for the treatment of SARS-Cov-2 disease."],"journal":"In Vivo","authors":["Bimonte, Sabrina","Crispo, Anna","Amore, Alfonso","Celentano, Egidio","Cuomo, Arturo","Cascella, Marco"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503817","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.21873/invivo.11949","keywords":["covid-19","sars-cov-2","antiviral drugs","coronaviruses","review","tocilizumab","virus"],"e_drugs":["tocilizumab","chloroquine diphosphate","lopinavir-ritonavir drug combination","remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1668892488189870080,"score":152.78625}]}